Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Telapristone Acetate (Proellex®) in the Treatment of Pre-Menopausal Women With Confirmed, Symptomatic Endometriosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult females between 18 and 47 years of age using prescription analgesics for endometriosis pain and with a Biberoglu Behrman Symptom Severity Scale (BBSS) score ≥7 at screening (assessed over the previous 28 days).~* Endometriosis diagnosis must have been surgically confirmed within 7 years. A laparoscopic diagnosis is acceptable.~* Participants must have a history of at least 3 regular menstrual cycles in which symptoms of endometriosis occurred immediately prior to screening.~* Normal or abnormal but non-clinically significant transvaginal ultrasound.~* History of menstrual events occurring in regular cycles.~* Agreement not to attempt to become pregnant during the trial.~* Agreement to limit alcohol consumption to no more than 2 drinks per week and to avoid alcohol consumption within 48 hours before each visit.~* Ability to complete a daily electronic participant diary and study procedures in compliance with the protocol.~* Women of child-bearing potential must be willing to use double-barrier contraception during the study and for 30 days after discontinuation of study medication. Acceptable double-barrier methods are: male condom with spermicide; male condom with diaphragm; diaphragm containing spermicide plus additional intra-vaginal spermicide.~* Has a negative pregnancy test at the Screening and Baseline visits, and subsequent study visits.~* A Body Mass Index (BMI) between 18 and 39 inclusive.~* Is available for all treatment and follow-up visits.~Exclusion Criteria:~* Post-menopausal woman, defined as either; six (6) months or more (immediately prior to screening visit) without a menstrual period, or prior hysterectomy and/or oophorectomy.~* Pregnant or lactating or is attempting or expecting to become pregnant during the 6-7 month study period.~* Women with abnormally high liver enzymes or liver disease \[alanine transaminase (ALT) or aspartate aminotransferase (AST) exceeding 2 x upper limit of normal (ULN) and total bilirubin exceeding 1.5 x ULN at screening and confirmed on repeat\].~* Received an investigational drug in the 30 days prior to the screening for this study.~* History of polycystic ovary syndrome (PCOS).~* Concurrent use of any testosterone, androgen, anabolic steroids, dehydroepiandrosterone (DHEA) or hormonal products for at least 2 weeks prior to screening and during the study. Oral contraceptive use for control of endometriosis symptoms is acceptable for the first 28-days of the study.~* Use of Depo-Provera® in the preceding 6 months.~* Use of Gonadotrophin releasing hormone (GnRH) as (e.g. Lupron Depot) within 3 months of the first dose of study drug (Lupron Depot must have a wash-out period of 3 months after the period of duration of the Lupron dose).~* Has an intrauterine device (IUD) in place. Copper IUDs (non-hormone containing will be permitted).~* Presence of intramural fibroids that impact the endometrial stripe, submucosal fibroids (any size), or endometrial polyps. Subserosal and intramural fibroids with no impact on the endometrial stripe are acceptable.~* Presence of endometrioma(s).~* Present history or condition that causes non-endometriosis related dyspareunia (e.g. vulvar vestibulitis).~* Past or present history of thrombophlebitis or thromboembolic disorders.~* Known or suspected carcinoma of the breast or reproductive organs.~* History of abnormal electrocardiogram (ECG) that, in the opinion of the investigator, is clinically significant and will prevent the participant from completing the study, including a QTc (corrected QT interval) of greater than 450 milliseconds (ms).~* Cervical dysplasia classified as Atypical Squamous Cells of Undetermined Significance (ASCUS) associated with high-risk human papilloma virus (HPV) or Low/High Grade Squamous Intraepithelial Lesion (LGSIL or HGSIL).~* History of abnormal endometrial biopsy including the presence of Endometrial Intraepithelial Neoplasia (EIN).~* Recent history (within past 6 months) of alcoholism or drug abuse.~* Known active infection with Human Immunodeficiency Virus (HIV), Hepatitis A, B or C.~* Previous history of auto-immune disease and/or positive antinuclear antigen (ANA).~* Endometrial stripe ≥18 mm in thickness at Visit 1.~* Women currently taking cimetidine or spironolactone.~* Clinically significant abnormal findings on screening examination and laboratory assessments or any condition which in the opinion of the investigator would interfere with the participant's ability to comply with the study instructions or endanger the participant if she took part in the study.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 47 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Following the Stage 1 no treatment baseline assessment period, placebo matching capsules, orally, once daily for 18 weeks in Stage 2. Eligible participants had the option to receive 2 additional 16-week cycles of active treatment at 12 milligrams (mg)/day separated by an off-drug interval (ODI) in Stage 3.
- Telapristone acetate 6 mg (Type: EXPERIMENTAL): Following the Stage 1 no treatment baseline assessment period, telapristone acetate (Proellex®) 6 mg capsules, orally once daily for 18 weeks in Stage 2. Eligible participants had the option to receive 2 additional 16-week cycles of active treatment at 6 mg/day separated by an ODI in Stage 3.
- Telapristone acetate 12 mg (Type: EXPERIMENTAL): Following the Stage 1 no treatment baseline assessment period, telapristone acetate (Proellex®) 12 mg capsules, orally once daily for 18 weeks. Eligible participants had the option to receive 2 additional 16-week cycles of active treatment at 12 mg/day separated by an ODI in Stage 3.

Based on this trial design, predict the completion outcome and termination type (if applicable).